Genome×Neuroscience

Massive human genomic resources (biobanks, constraint maps) and cellular brain atlases are converging toward a mechanistic map linking genetic variation to neural circuit and behavioral phenotypes. The fusion zone is population-scale neurogenomics: using genome-wide constraint and expression data to explain why specific brain cell types and gut-brain signaling pathways drive neurological and psychiatric disease.

The two communities don't co-publish yet, but they already share heavy bridge infrastructure — ENCODE (functional genome annotation), population cohorts, in vivo models, cell biology, and data science. 61 authors publish on both sides separately, and Adamic-Adar affinity of 7.8 with 33 common neighbours signals a dense shared methods substrate. The representative papers show both sides independently maturing: deep-phenotyped biobanks and mutational-constraint atlases on one side, single-cell brain architecture and gut-brain axis mechanisms on the other. They are one shared dataset away from direct collision.

Groups sitting on the bridge win: teams that pair large genotyped-and-phenotyped cohorts with single-cell/spatial brain atlases and can run variant-to-cell-type-to-circuit inference. Expect the edge to go to consortium-scale efforts fluent in both statistical genetics (GWAS, constraint, fine-mapping) and cellular neuroscience, plus data-science teams building the integration layer. Microbiome-literate neuroscience labs are a wildcard second front via the gut-brain axis.

A variant-to-cell-type-to-circuit pipeline: take mutational-constraint and fine-mapped GWAS signals for a psychiatric/neurodegenerative trait from a large biobank, project them onto single-cell brain atlas expression to nominate causal cell types, then validate in in vivo models — with a parallel arm testing whether gut-brain-axis genes explain a fraction of the constraint-enriched risk. Deliverable: an open constraint-weighted brain cell-type risk map.